FROM THE EDITOR

SGLT-2 inhibitors: Diabetes and CKD and CHF (and gout?), oh my! 392
What mechanisms might account for the diverse beneficial effects of the SGLT-2 inhibitors observed across various diseases?
Brian F. Mandell, MD, PhD

THE CLINICAL PICTURE

Varicose veins 401
A 60-year-old man presented with a 20-year history of slowly worsening prominent veins in both lower limbs.
Noelle Boctor, MD; Paul Aronowitz, MD

1-MINUTE CONSULT

Do patients with sepsis benefit from intravenous albumin? 405
Patients with sepsis who do not need vasopressors do not benefit from intravenous albumin compared with intravenous crystalloid therapy alone.
Ryan Dunn, MD; Kealy Ham, MD; Lisa Marks, MLS, AHIP; Neera Agrwal, MD, PhD

1-MINUTE CONSULT

Does my patient with acute variceal hemorrhage need a transjugular intrahepatic portosystemic shunt? 409
Placement of a transjugular intrahepatic portosystemic shunt can be used as salvage therapy to control bleeding when endoscopic management fails and as a means of secondary prophylaxis in select patients.
Mahnur Haider, MD; Indira Bhavsar-Burke, MD; Robert S. O’Shea, MD, MSCE; Christina C. Lindenmeyer, MD

CONTINUED ON PAGE 390
CONTINUED FROM PAGE 389

**REVIEW**

**SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists** 415
This review summarizes recent data and guidelines regarding SGLT-2 inhibitors in heart failure and chronic kidney disease and provides practical guidance for their use.

Rahul Jaswaney, MD; Samantha Sokoloff, MD; Val Rakita, MD; Daniel J. Rubin, MD, MSc

**Lymphedema vs lipedema: Similar but different** 425
Lymphedema, lipedema, and even simple obesity in the extremities can resemble each other superficially and are often confused for one another, but they differ in important ways.

Laura Daniela Lomeli, BA; Vinni Makin, MD; John R. Bartholomew, MD; Bartolome Burguera, MD, PhD

**Preventing herpes zoster in immunocompromised patients: Current concepts** 437
The authors review clinical aspects of herpes zoster vaccination, including identifying at-risk patients, weighing the risks and benefits of the recombinant zoster vaccine, and using best practices for administering the vaccine.

Cassandra Calabrese, DO; Elizabeth Kirchner, DNP; James Fernandez, MD, PhD; Leonard H. Calabrese, DO

**LETTERS TO THE EDITOR**

**Severe hyponatremia: Are you monitoring the urine output?** 397

Anup Katyal, MD; Ashwani Joshi, MD

In reply: Severe hyponatremia: Are you monitoring the urine output? 397

Elias Bassil, MD; Georges N. Nakhoul, MD, MEd; Jonathan J. Taliercio, DO; Ali Mehdi, MD, MEd

**DEPARTMENTS**

CME Calendar 394
CME/MOC Instructions 446

---

Visit WWW.CCJM.ORG
Test your knowledge of clinical topics and earn
*AMA PRA Category 1 Credit™* and *ABIM MOC points*